Presentation Information
[P2-13]Validation of an ultra-sensitive PCR assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)
*Nathalie Bernard1, Sara Diels3, Bart Tegenbos3, Dirk Goossens3, Lien Heyrman4, Jurgen Del Favero4, Magdalena Stolarek2, Sam Abujudeh, Barnaby Balmforth2 (1. Scientific Business Development, CellCarta NV, 2. Biofidelity Ltd, 3. Assay Development Team, CellCarta NV, 4. Global Operations, CellCarta NV)
Keywords:
biomarker,NSCLC,CTA
Password required to view
Log in
or
Comment
To browse or post comments, you must log in.Log in